Background

Asthma is a consequence of complex gene–environment interactions. Exploring the heterogeneity of asthma in different stages is contributing to our understanding of its pathogenesis and the development of new therapeutic strategies, especially in severe cases.

Objective

This study aimed to further understand the relationship between manifestations of acute and chronic asthma and various endotypes, and explore the severity of lung inflammation, cell types, cytokine/chemokine differences, and the effects of FIP-fve.

Materials and methods

Acute and chronic OVA-sensitization mouse asthma models, based on our previously published method, were used and FIP-fve was used to evaluate the effect on these two models. BALF cytokines/chemokines were detected according to the manufacturer's protocol.

Results

Seventeen cytokine/chemokine secretions were higher in the chronic stage than in the acute stage. Whether in acute stage or chronic stage, the FIP-fve treatment groups had reduced airway hyperresponsiveness, infiltration of airway inflammatory cells, secretion of cytokines, chemokines by Th2 cells, and TNF-α, IL-8, IL-17, CXCL-1, CXCL-10, CCL-17, and CCL-22, and it was also found that the Treg cell cytokine IL-10 had increased significantly. PCA (Principal Component Analysis) was also used to compare statistics and laboratory data to find the important biomarkers in different stages and after treatment with FIP-fve.

Conclusions

There are many different immune responses in the different stages of the asthma process. Drug treatment at the appropriate times might help reduce the worsening of asthma.

中文翻译：

---

生物标记物的作用和FIP-fve在急慢性动物哮喘模型中的作用。

背景

哮喘是复杂的基因与环境相互作用的结果。探索哮喘不同阶段的异质性有助于我们了解哮喘的发病机理和开发新的治疗策略，特别是在严重病例中。

目的

这项研究旨在进一步了解急性和慢性哮喘的表现与各种内型之间的关系，并探讨肺部炎症的严重程度，细胞类型，细胞因子/趋化因子的差异以及FIP- fve的作用。

材料和方法

根据我们先前发表的方法，使用了急性和慢性OVA致敏小鼠哮喘模型，并使用FIP- fve评估了这两种模型的效果。根据制造商的协议检测BALF细胞因子/趋化因子。

结果

慢性期的十七种细胞因子/趋化因子分泌高于急性期。无论在急性期还是慢性期，FIP- fve治疗组均降低了气道高反应性，气道炎性细胞浸润，Th2细胞分泌细胞因子，趋化因子以及TNF-α，IL-8，IL-17，CXCL-1 ，CXCL-10，CCL-17和CCL-22，并且还发现Treg细胞的细胞因子IL-10显着增加。PCA（主成分分析）还用于比较统计数据和实验室数据，以发现不同阶段以及经FIP- veve治疗后的重要生物标志物。

结论

在哮喘过程的不同阶段，存在许多不同的免疫反应。在适当的时候进行药物治疗可能有助于减轻哮喘的恶化。